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Abstract
Precision medicine is a medical model aiming to deliver customised healthcare - with medical decisions, practices, and/or
products tailored to the individual patient informed but not directed by guidelines. Allergen immunotherapy has unique
immunological rationale, since the approach is tailored to the specific IgE spectrum of an individual and modifies the
natural course of the disease as it has a persistent efficacy after completion of treatment. In this perspective Allergen
Immunotherapy - AIT has to be presently considered a prototype of Precision Medicine.
Precise information and biomarkers provided by systems medicine and network medicine will address the discovery of
Allergen immunotherapy biomarkers for (i) identification of the causes, (ii) stratification of eligible patients for AIT and
(iii) the assessment of AIT efficacy.
This area of medical technology is evolving rapidly and, compelemented by e-health, will change the way we
practice medicine. It will help to monitor patients’ disease control and data for (i) patient stratification, (ii) clinical
trials, (iii) monitoring the efficacy and safety of targeted therapies which are critical for reaching an appropriate
reimbursement. Biomarkers associated with e-health combined with a clinical decision support system (CDSS) will
change the scope of Allergen immunotherapy.
The cost/effectiveness of Allergen immunotherapy is a key issue for successful implementation. It should include
the long-term benefits in the pharmaco-economic evaluation, since no other allergy treatment has this specific
characteristic.
AIT is the prototype of current and future precision medicine.
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Introduction
Several terms including “personalized medicine”, “precision
medicine”, “stratified medicine”, “targeted medicine” and
“pharmacogenomics” are used interchangeably [1] but dif-
fer subtly. “Precision medicine” is similar to “personalized
medicine” and is a new term encompassing one of the
foremost examples of future disruptive innovation in
healthcare. It is a medical model aiming at the custo-
mization of healthcare - with medical decisions, practices,
and/or products tailored to the individual patient. It also
refers to the tailoring of medical treatment to the indi-
vidual characteristics of each patient [1]. In this model,
based on the knowledge of mechanisms of the disease,
personalized medicine generally involves the use of two
medical domains, typically a diagnostic process and a
therapeutic product, to select appropriate and optimal
management, and to improve patients’ outcomes [2, 3]
(Fig. 1). The term “personalized medicine” was first coined
in the context of genetics, though it has since broadened
to encompass many types of personalization measures.
“Stratification” refers to the division of patients with a
specific disease into subgroups based on a particular
characteristic and who respond more frequently (or
better) to a treatment or alternatively are at decreased
risk of side effects in response to a certain treatment.
The concept of precision medicine is not new: clinicians
have long observed that patients with similar symptoms
may have different illnesses, with different causes, and
similarly that medical interventions may work well in
some patients with the same disease. What is new is
that advances in a wide range of fields from genomics,
other omic sciences, to medical imaging to regenerative
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medicine, along with increased computational power
and the advent of mobile and wireless capability and
other technologies are allowing patients to be treated
and monitored more precisely and effectively in ways
that better meet their individual needs [1]. One of the
recent examples is cystic fibrosis: the detection of the
causative molecular mechanism of the disease in 4 % of
the patients permitted a specific intervention which led
to a complete reversion of the disorder [4]. The real
and practical relevance in our society of precision
medicine was highlighted by a new initiative launched
in January 2015 by President Obama for cancer and
diabetes mainly [5].
Precision medicine will cause the end of the block-
buster era in pharmaceuticals through better insights
about the mechanisms of the diseases, the application of
stratification in medicine, focussed research on drug
safety and a model for financial return [6] (Table 1).
There is an urgent need to adopt phenotype-driven therapy
especially when expensive drugs such as biologics or
biosimilars are prescribed [6]. This is fundamental to the
sustainability of Health Care Spending.
AIT is a (current) (Table 2) and (future) (Table 3)
paradigm of Precision Medicine [7]. It involves a precise
diagnostic assessment of the patient, as well as the stra-
tification and application of a targetted therapeutic
product (Fig. 2).
Review
Immunologic rationale
Immunoglobulin E (IgE) mediated allergic diseases are
characterised by heterogeneous clinical phenotypes and a
large variety of different sensitisation patterns. Patients may
be sensitized to few or many allergens (monoclonal, oligo-
clonal or polyclonal sensitization), may express various
clinical organ manifestations (allergic rhinoconjunctivitis,
atopic dermatitis, asthma, food allergy) with or without
systemic reflection of the local IgE antibody responses,
and may show different progression in terms of onset of
disease, immune response patterns, organ involvement
and severity of symptoms.
Treatment strategies therefore need to be individualized:
from primary to tertiary prevention to organ-specific
symptomatic pharmacotherapy. Furthermore, preventive
or causal treatment with AIT aiming at relevant allergens
should complement each other depending on the
sensitization pattern of the patient and on his/her clinical
presentation. Organ manifestations, severity and course of
disease as well as response to allergen avoidance and
pharmacological treatment and the level of control
achieved by those treatments should be evaluated based
on history, questionnaires and clinical investigations.
Furthermore, the presence of IgE-mediated sensitization
should be tested using a simple screening test based on
the 4–8 most frequent allergens or allergen mixtures
(Phadiatop principle) allowing for a broad application at
the GP/pharmacy level. A standardized skin prick test
may serve this purpose; for Europe, a panel of allergen
extracts relevant to the regions has been defined [10].
With a positive skin prick test confirming that sen-
sitization to allergens is present in an individual patient
and that natural allergen exposure of the patient leads to
respiratory symptoms, specific profiling of IgE sensitisation
may be performed. The component-resolved molecular
diagnostic tool (CRD) can be used to decipher the patient’s
sensitization patterns and cross-reactivities at the mole-
cular level [11]. CRD supports the prediction of the risk of
severe reactions to specific allergens as well as the predic-
tion of disease development in an individual patient, and
thus allows an evaluation of the risk of disease comorbidi-
ties and exacerbations, and consequently appropriate risk
management (risk stratification). However, there may
Fig. 1 The three steps of personalised (precision) medicine (modified from [2])
Table 1 Major achievements of precision medicine
• Improve clinical outcomes and predictability
• Avoid side effects caused by inappropriate treatment
• Increase quality of life
• Encourage patient compliance due to better results
• Optimise use of healthcare resources
Table 2 Current precision medicine in AIT
1. Precise diagnosis with history, skin prick tests and specific IgE
2. Proven indications: Allergic rhinitis and conjunctivitis, asthma,
venom allergy
3. Patient stratification: those who require AIT for the control of
symptoms and the alteration of the natural history of allergy
4. Innovative product: allergen standardized, evidence medicine
based and with marketing authorization
5. Placing the patient’s (and caregiver)’s wishes and goals at the
centre an essential component
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be difficulties in the interpretation of certain CRD
results [12, 13].
CRD also helps to improve the selection of the allergen
product for AIT of an individual patient [14]. Ideally, IgE
specificities of the patient and allergens in the product
should match CRD represents a useful tool to distinguish
genuine sensitisations from cross-reactions specifically in
poly-sensitized patients, when traditional diagnostic tests
and clinical history are unable to precisely identify the
relevant allergen(s) for AIT. The approach of AIT is
“precise” and tailored to the specific IgE spectrum of the
individual. As AIT only modifies the immune response
against the allergen for which it is being administered. a
precise etiological diagnosis is required. Non specific
cross-reactive binding to profilins [15] or cross-reactive
carbohydrate determinants (CCDs) [16] need to be
excluded, and the allergen molecule pattern, reflecting
minor and major allergens, needs to be established.
Therefore, the selection of an AIT product is necessarily a
precise, precision approach.
In patients with sensitizations of questionable clinical
relevance at the mucosal level, a target organ provoca-
tion test may be indicated before the initiation of AIT.
Although not broadly available, conjunctival and nasal
allergen provocation tests may confirm or reject specific
allergens as causal agents of organ-specific disease.
Upon the application of the precise individualized
allergen composition [17], allergen tolerance is created
and induced by several mechanisms, including alterations
of the allergen-specific IgE, IgG4 and IgG isotypes with
the generation of blocking antibodies corresponding to
the allergens in the AIT [18, 19]. Allergen tolerance also
includes the induction of allergen-specific regulatory
subsets of T and B cells, releasing immune-suppressive
secreted factors such as IL-10 and TGF-β [20]. As a
consequence, allergen-specific inflammatory responses
by mast cells, basophils and eosinophils in inflamed
tissues are down-regulated, leading to diminished early-
and late-phase responses to the administered allergens.
It is likely that mechanisms of SLIT are not identical to
those of SCIT [21].
Predictive markers of response
Biomarkers
Biomarkers, defined as characteristics that indicate bio-
logical processes, are essential for monitoring the health
of both individuals and communities. Biomarkers include
physical examinations (e.g. blood pressure), biological and
genetic tests, as well as others that can be objectively
measured and used as indicators of pathogenic processes
and changes which may occur as a result of treatment
[22]. As such, they hold the potential for improving (i) the
understanding of molecular mechanisms of diseases, (ii)
identification of possible new disease pathways, (iii) pre-
diction models of complex diseases, (iv) the determination
of the level of biological activity of the disease, (v) refine-
ment of disease phenotypes that may respond differently
to specific treatments, (vi) the monitoring of treatment
responses, and (vii) the potential application of precision
medicine [23, 24]. Although much of the biomarker re-
search in asthma and allergy to date has focused on genet-
ics and genomics, in recent years, strategies that involve
direct measurement of multiple protein concentrations
have received increasing attention. Biomarkers are attract-
ive as they may provide stronger signals of association
with phenotypes of interest and because advances in
biotechnology have made it possible to simultaneously
measure concentrations of hundreds of candidate pro-
teins in serum and other bio-fluids and, in turn, to
investigate at the protein level the involvement of
multiple pathways in disease risk [25, 26]. Biomarkers
can change over time in response to a broad range of
hostand environmental factors as well as treatment.
Most biomarker studies in asthma and allergic diseases
have used serum or plasma samples, which are relatively
Table 3 Future precision medicine in AIT
1. Precision diagnosis aided by eHealth technologies [8, 9], enhanced
Component-resolved diagnostics (CRD), genomics and other future
possibilities
2. Amenability of Allergic rhinitis, asthma, co-morbid allergic diseases,
venom allergy, food allergy, other diseases (eg atopic dermatitis) to
treatment with AIT
3. Patient stratification aided by e-HEALTH assessment and biomarkers
4. Innovative products: recombinant allergens and new forms of AIT
5. Marketing authorization for AIT products
6. A new role of preventative immunotherapy aimed at those at
high risk
7. Putting the patient at the centre: guideline informed rather than
guideline directed.
Fig. 2 The three steps of Personalised (Precision) Medicine applied to AIT
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easy to collect and process. Serum biomarker studies may
be particularly effective in illnesses that, similar to allergic
diseases, have significant systemic components and/or
multi-organ manifestations [27]. Substantial progress in
molecular immunology coupled with an increasing focus
on translational research has resulted in a rapid expansion
of immune biomarkers in recent years. These hold great
promise to deliver future candidate biomarkers in
immune-mediated diseases {Willis, 2015 #31843} including
allergic diseases {Sorensen, 2011 #31846}.
There is a lack of biomarkers for many NCDs, their
co-morbidities, disease severity and activity. This is
creating a bottleneck in the discovery and development of
new medicines as identified by the Innovative Medicines
Initiative (IMI).
Single biomarkers and their combinations should be
developed from the knowledge of mechanisms to refine
and empower diagnosis (classification), find novel thera-
peutic approaches and better understand disease pro-
gression and prognosis (stratification). The evaluation
framework of biomarkers should consist of 3 steps [28]
(Table 4).
Biomarkers in allergic diseases and asthma are of great
importance and a large body of research has been started.
Biomarker identification is based on systems biology
approaches combining transcriptomics, proteomics, epi-
genetics and metabolomics in a large patient cohort. Two
EU-funded projects are currently ongoing: U-BIOPRED
(IMI) in severe asthma [29, 30] and MeDALL (FP7) in al-
lergy (27, 30 ). MeDALL has already made critical obser-
vations concerning IgE biomarkers for the diagnosis and
prognosis of allergic diseases [17, 31]. It is hoped that
these projects will help to find biomarkers for AIT efficacy
and safety, and to make precision medicine possible [32].
In AIT, 5 types of biomarkers are needed (Table 5).
Precision medicine using e-health, integrated care
pathways (ICP) and a clinical decision support system (CDSS)
Identifying the most suitable patients for whom an inter-
vention is appropriate is critical for the delivery of a cost-
effective health system. In many diseases, the management
of patients uses ICT (information communication technol-
ogy) tools including integrated care pathways, e-health and
clinical decision support systems (CDSS). This has made a
significant improvement and has sometimes led to a
change of management in health systems.
Integrated Care Pathways (ICPs) differ from practice
guidelines as they are utilized by a multidisciplinary
team and have a focus on the quality and co-ordination
of care [33]. An ICP is intended to act as a guide to
treatment. Clinicians are free to exercise their own
professional judgments as appropriate. However, any
alteration to the practice identified within this ICP must
be noted as a variance [34].
Integrated Care Pathways for asthma and rhinitis co-
morbidity (AIRWAYS-ICP) are multisectoral ICPs which
can be used across Europe and other countries. They
allow a variance analysis on the diagnosis and treatment
of allergic diseases in different European countries and
regions [8]. In the future, it is expected that AIRWAYS-
ICPs will be linked with pay-for-performance (P4P),
audit and feedback, as well as integration of recommen-
dations with electronic medical records. AIRWAYS-ICPs
place a particular interest in cultural and societal aspects
of the diseases in a project centred around the patient.
AIRWAYS ICPs represent the model of NCD used by
the European Innovation Partnership on Active and
Healthy Ageing [35] and will be used as a model for
deployment and scale up of chronic diseases by the EIP
on AHA.
Telemonitoring permits the monitoring of patients
on a regular basis. Pollen allergy using electronic
data management of sensitized patients has been
proposed by the European Allergy Network (EAN)
(www.pollenwarndienst.com). The allergy sentinel net-
work, approved by AIRWAYS-ICPs, is a very simple
iPhone/Android App which is already available and which
is being expanded to other systems with interoperability.
It is initially being deployed in 13 different countries with
14 languages. Current status is measured daily by the use
of VAS ( Visual Analogue Scales) which represent reliable
and valid measures of rhinitis control [36, 37]. It can be
used across the life cycle [38–40]. Daily, 4 VAS (global
evaluation, nasal, ocular and bronchial symptoms) are
filled in by the patient on a cell phone and the information
Table 4 Steps for the evaluation framework of biomarkers
• Analytical validation of reliability, reproducibility, and adequate
sensitivity and specificity.
• Qualification to ensure that the biomarker is associated with the
clinical outcome including prognosis.
• Utilisation analysis to determine that the biomarker is appropriate
for the proposed use.
Table 5 Types of biomarkers for AIT
1. Identification and validation of biomarkers assessing the probability
of response to treatment of AIT before it is initiated
2. Identification and validation of biomarkers assessing the safety of
AIT before it is initiated
3. Identification and validation of biomarkers confirming the efficacy
of AIT in patients receiving AIT (short and long term)
4. Identification and validation of biomarkers predicting the long-term
effects of AIT before it is stopped
5. Identification and validation of biomarkers predicting the relapse of
symptoms when AIT is stopped
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is sent to a clinical decision support system (CDSS) for an
optimal management of the patients.
The clinical decision support system (CDSS), an inter-
active computer software, is designed to assist health
professionals with decision making tasks, such as deter-
mining treatment strategies of patient using the results
of ICPs. This knowledge management provides clinical
advice for patient care. The chronic respiratory diseases
CDSS (AIRWAYS-CDSS) will be based on the ARIA
2015 revision (in preparation) to allow standardisation
of patient management. It will also enable patient stra-
tification. Patients with uncontrolled disease based on
VAS telemonitoring despite optimal treatment according
to guidelines will be considered as SCUAD (severe
chronic upper airway diseases) [41]. However, However
the dialogue to date suggests that this sis a support tool
for patients and that the CDSS will prompt the patient
concerning different treatment options.
These 3 innovative tools (AIRWAYS-ICP, allergy senti-
nel network and AIRWAYS-CDSS) will be combined in
the MACVIA-ARIA Sentinel NetworK (MASK) and will
make it possible to assess some of the unmet research
needs in AIT (Table 6).
These tools can provide valuable information on most
parameters for randomized controlled trials (RCTs) in
AIT [42] (Table 7).
Biomarkers and e-health in preschool children
To date, AIT has only been considered after 5 years of
age in most recommendations, but newer ones will ad-
vocate this form of treatment in highly selected children
from 3 years of age. Pre-school children who may be
candidates for SLIT are those sensitized to indoor aller-
gens (mites) with co-morbid asthma and rhinitis [45–47]
and possibly those with polysensitization [31] or pollen
allergic children with demonstrated symptoms during
the season. It is likely that CRD will be of great value in
the identification and stratification of preschool children
who might benefit from early AIT. VAS can be used
satisfactorily by caregivers of preschool children [39]
with e-health providing an innovative tool for monitoring
outcomes..
The combination of biomarkers with MASK will
represent a novel tool to diagnose, stratify, manage and
assess treatment efficacy in allergic patients.
Understanding the economic burden of
uncontrolled and under-treated allergic
respiratory disease (allergic rhinitis and asthma)
Respiratory diseases place a huge burden on society in
terms of disability and premature mortality. They also have
an impact on direct costs (health service and drugs pre-
scribed) and on indirect costs related to lost production.
Allergic rhinitis
Allergic rhinitis is one of the most common diseases
globally, in all age groups and in all countries. Many
patients do not seek medical care because the disease is
often underestimated or unrecognised by patients as well
as by health care professionals.
Patients may not understand the benefits of treatment
and compliance to treatment may then be poor. A sub-
stantial proportion of patients can be managed by optimal
pharmacological treatment [1]. However, a subset of pa-
tients (10 to 20 %) is poorly controlled and is ascribed to
SCUAD (severe chronic upper airway disease) (41, 48, 49).
Asthma is often associated with allergy and it is well
known that severe asthma has an important impact on
the health system [48- 51].
Allergists and their patients know that the symptoms
of allergic diseases can disturb sleep, worsen mood,
decrease energy levels, impair quality of life and weaken
the ability to concentrate. In children, these factors
impact performance at school [52], potentially frustra-
ting ambitions for higher education and impairing active
and healthy ageing [53]. In the work environment, im-
paired concentration leads to decreased productivity, a
phenomenon recognised as presenteeism, which has a
consequent negative economic impact. The patient also
Table 6 Precision medicine in AIT using innovative tools
(biomarkers and e-health)
• Assessment of prevalence and severity of allergic diseases.
• Phenotypic characterisation of allergic patients, stratification of
patients, characterisation of severe chronic upper airway disease
(SCUAD) patients and characterisation of patients to be treated
by AIT.
• Randomised controlled trials (placebo-controlled or real life cluster
randomised trials): assessment of efficacy (during the allergen
exposure) and safety (during AIT administration).
• Follow up of patients in clinical settings during AIT.
• Follow up of patients in clinical settings after AIT has been stopped.
Table 7 Use of biomarkers and e-health in AIT randomized
controlled trials
EAACI AIT outcomes e-health and biomarkers
Total symptom score Included in VASa
Total medication score Standardised by ICPs and CDSS
Total symptom-medication score Standardised by ICPs and CDSS
Quality-of-Life Included in VASa
Well days Standardised by ICPs and CDSS
Days with severe symptoms Standardised by ICPs and CDSS
Global assessment of patient
satisfaction
Recorded by telemedicine
aIn 2 cluster randomized trials of 595 and 537 patients (one in secondary care,
one in primary care) [43, 44], the VAS level change during treatment
incorporated symptom and RQLQ information.
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suffers an economic burden. Multiple visits to the
physician, multiple prescription costs and potentially the
costs of side effects of medications, particularly when first
generation antihistamines [9] are prescribed, all constitute
a significant amount of direct cost. Time off work due to
absenteeism as well as reduced performance at work also
represent an economic burden to the patient.
A recent GA2LEN review limited to the European
Union attempted to assess the costs of allergic diseases.
Although the study was carefully performed, it did not
include a sufficient sensitivity analysis with the resulting
published costs (between 55 and 151 billion € per year)
coming in at the higher levels of expectation [54]. This
study rightly pointed out that there is an urgent need to
treat patients appropriately, an achievement which would
likely reduce indirect costs.
Asthma
The prevalence of asthma in developed countries is
around 10 % [55] with large differences between countries.
Prevalence in emerging countries is sometime lower but
continues to rise sharply with increasing urbanization and
westernization [56, 57]. It is estimated that 300 million
people suffer from asthma globally [58].
In 2012, the European Respiratory Society published a
white book [59, 60]. In asthma, the annual cost of health
care and lost productivity is about €34 billion in the 28
countries of the EU. The average direct healthcare cost
per case in asthma is about €2000 per year, often over
several decades. The value of Disability-adjusted life-
years (DALYs) lost is €38 billion in asthma leading to a
total cost (direct + indirect + DALYs) of about €72 billion
in the EU [59, 60].
Allergen immunotherapy is a cost effective treatment
Cox and Hankin reviewed studies from health systems
in North America and in southern, central and northern
Europe, in which AIT and symptomatic drug therapy
were used to treat a range of perennial and seasonal al-
lergic conditions [61]. Twenty-four studies met their in-
clusion criteria, and all but one of the studies concluded
that AIT was associated with cost savings (relative to
symptomatic drug therapy). The savings range from a
few hundred dollars/euros to a few thousand per year.
The only study which failed to demonstrate savings for
AIT was a double-blind, randomized, placebo-controlled
trial published in 1996, which was limited in that it only
compared the costs of medication for the first two years
of SCIT (relative to standard treatment) in 77 adoles-
cents and adults with ragweed-pollen-induced asthma
[62]. However, many of these studies were based on
assumptions of the preventive effect of AIT using pre-
diction models.
Nine studies looked at the health economics of SCIT,
eight looked at SLIT tablet formulations, two covered
liquid SLIT products, four compared the health eco-
nomics of SLIT, SCIT and standard treatment and one
compared the health economics of SCIT and SLIT [63].
A variety of models were used: comparative cost ana-
lysis, a decision-tree cost model, a Markov model and an
analysis of the savings associated with symptom-free
days. Of the six studies comparing SLIT with SCIT, four
found cost savings for SLIT and two found cost savings
for SCIT. In a recently published study [64], a 5-grass
pollen SLIT tablet administered with a pre- and co-
seasonal regimen was associated with significant cost
savings compared with year-round SCIT ($2471), seasonal
SCIT ($948) and a single-grass pollen SLIT tablet admin-
istered year-round ($1168).
A health technology assessment examined the com-
parative costs of SLIT and SCIT. Benefit from both SCIT
and SLIT compared with placebo was consistently dem-
onstrated, but the extent of this effectiveness in terms of
clinical benefit is as yet unclear [65]. Both SCIT and
SLIT may be cost-effective compared with SDT from
around 6 years (threshold of £20,000-30,000 per QALY).
The authors concluded that further research is needed
to establish the comparative effectiveness of SCIT com-
pared with SLIT and to provide more robust cost-
effectiveness estimates.
Given the relatively high numbers needed to treat
(to obtain benefit) and low numbers needed to harm,
it becomes more attractive to consider a strategy which
fundamentally alters the disease trajectory. Of equal
importance is improving patient selection which should
reduce the numbers needed to treat to see benefit, thus
substantially reducing overall costs.
Over the life course of the individual, the picture of
AIT becomes more attractive economically given the
demonstrated societal economic benefits, the reduced
healthcare costs and the reduction in economic costs to
the individual patient.
Concluding remarks
The aim of this article was to review and position AIT
in the context of Precision Medicine.
AIT has unique immunological rationale, since the
approach is tailored to the specific IgE spectrum of an
individual and modifies the natural course of the disease
as it demonstrates persistent efficacy after cessation of
active treatment.
Precise information and biomarkers provided by
systems medicine [32] and network medicine [66] will
address the discovery of AIT biomarkers for (i) precise
identification of aetiology, which leads to (ii) strati-
fication of patients eligible for AIT ( i.e. patient selection)
and (iii) assessment of AIT efficacy.
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This area of medical technology is evolving rapidly
with e-health influencing the way we practice medicine.
Biomarkers associated with e-health and a clinical deci-
sion support system will change the scope of AIT. It will
help to monitor the patient’s control and will provide
data for (i) patient stratification, (ii) clinical trials, (iii)
monitoring the efficacy and safety of targeted therapies,
all of which are critical components for achieving appro-
priate reimbursement.
The cost/effectiveness of AIT is a key issue for patients
and purchasers. It should include long-term effects and
benefits in the pharmaco-economic evaluation, since no
other current allergy treatment has this specific charac-
teristic of disease modification. Similarly, the costs of po-
tential harms, in particular due to side effects and lost
productivity, associated with current treatment modalities
need to be factored in.
The challenge: stratification of the patient requiring AIT
AIT can be initiated in two different situations that need
different considerations and to close different research/
therapeutic gaps:
 Identification of the patient most likely to benefit
from early intervention (prevention strategy). The
prevention of allergic diseases by the identification
of children who have developed asymptomatic
sensitization and early commencement of
immunotherapy is a hot topic but early results
are far from conclusive [67].
 The patient with severe uncontrolled disease
(treatment strategy). The subject of precision
medicine is of course the individual patient.
Impairment of quality of life with allergic rhinitis is
greater than that caused by asthma [68]. The
Fig. 3 Critical issues on precision medicine in AIT
Fig. 4 Flow of precision medicine approach in allergic disease
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negative impact of allergic diseases is not confined
to the patient alone: the activities of the whole
family, especially social, recreational and sporting,
may be governed by the need to avoid going outside,
for example. The immunologic and clinical
responses of allergic patients with severe disease and
multiple sensitisations need to be better understood
in terms of mechanisms, trajectories of diseases [31]
and response to AIT. The importance of
comorbidities and polysensitization merits further
investigation to improve our understanding of this
complex biodynamic. It is likely that a scoring
system will be developed combining risk factors
such as family history and early manifestation of
allergic disease coupled with evidence of
sensitisation by either skin prick test of specific
IgE or other biomarkers.This could identify the
population for whom such an approach might be
beneficial.
Precision medicine is therefore a paradigm for current
and future AIT (Fig. 3 and 4). Partnerships between the
allergy scientific community, manufacturers, all other
stakeholders in the healthcare system, politicians and
economists should be promoted and strengthened to
change the paradigm of AIT in medicine.
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